Treatment of pulmonary embolism and deep vein thrombosis with thrombolytic therapy.
Pulmonary embolism remains one of the most common causes of in-hospital death. Mortality is much greater in those patients who remain undiagnosed and without specific treatment. Thrombolytic therapy is a vital addition to the treatment of pulmonary embolism, deep venous thrombosis, and arterial thromboembolism.
D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007263:Infusions, Parenteral; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000503:physiopathology; D013300:Streptokinase / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator